Habib Bennaceur: Novo Nordisk Completed its Acquisition of Zaltenibart from Omeros Corporation
Habib Bennaceur, SVP Rare Disease Unit at Novo Nordisk, shared on LinkedIn:
”I am pleased to share that Novo Nordisk completed its acquisition of zaltenibart from Omeros Corporation strengthening our commitment to address unmet needs in rare blood and kidney disorders.
This addition expands our portfolio in haematology and renal as we continue working to serve more people and communities living with rare diseases.
Zaltenibart is an investigational antibody designed to precisely target MASP-3 in the complement system, representing a novel mechanism of action for our haemato-renal portfolio.
Early clinical data in paroxysmal nocturnal haemoglobinuria (PNH) is encouraging, and we look forward to advancing zaltenibart’s development and exploring its potential to provide new treatment options as we drive lasting change in rare disease.”
Stay updated with Hemostasis Today.
-
Dec 2, 2025, 11:49Marko Petrović: Proud to Present at the Oslo HEMS Conference 2025!
-
Dec 2, 2025, 11:14Amanda Farrin on Rustam Al-Shahi Salman’s Call to Arms: Great Messaging for the Opening Plenary at UKSF25
-
Dec 2, 2025, 10:59Catherine Thieblemont: Reappointed as Head of Department – A Joy, A Responsibility, and A Challenge that Remains Intact
-
Dec 2, 2025, 10:06Maeva May Shares Stroke Association’s New Research Strategy that Launched at UKSF2025
-
Dec 2, 2025, 10:00Jennifer Ficenec: What Happens to Blood Products After Hospitals Say No?
-
Dec 2, 2025, 09:55Marilena Vrana Reflects on A Year of Growth, Gratitude, and Collective Strength
-
Dec 2, 2025, 09:51Time to Refocus on NSTEMI․ Why This State-of-the-Art Review Matters
-
Dec 2, 2025, 09:51Arsène Mekinian: Corticosteroid Tapering Strategies Show No Difference
-
Dec 2, 2025, 09:50Joanna Sadowska: Bayer’s Asundexian Reduces Ischemic Stroke Risk in Phase 3 Trial